<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Neuropsychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Neuropsychopharmacol</journal-id><journal-id journal-id-type="publisher-id">ijnp</journal-id><journal-title-group><journal-title>International Journal of Neuropsychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">1461-1457</issn><issn pub-type="epub">1469-5111</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5616749</article-id><article-id pub-id-type="doi">10.1093/ijnp/pyw043.153</article-id><article-id pub-id-type="publisher-id">pyw043.153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Sunday Abstracts</subject></subj-group></subj-group></article-categories><title-group><article-title>PS153. Efficacy of ziprasidone monotherapy in patients with anxious depression: A 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Heo</surname><given-names>Jung Yoon</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Jeon</surname><given-names>Hong Jin</given-names></name><degrees>MD, PhD,</degrees><xref ref-type="aff" rid="aff1">a</xref><xref ref-type="aff" rid="aff2">b</xref><xref ref-type="aff" rid="aff3">c</xref></contrib><contrib contrib-type="author"><name><surname>Fava</surname><given-names>Maurizio</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Mischoulon</surname><given-names>David</given-names></name><degrees>MD, PhD,</degrees><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Baer</surname><given-names>Lee</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Clain</surname><given-names>Alisabet</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Doorley</surname><given-names>James</given-names></name><degrees>MA</degrees><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Pisoni</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Papakostas</surname><given-names>George I.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">b</xref></contrib></contrib-group><aff id="aff1">
<label>a</label>Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</aff><aff id="aff2">
<label>b</label>Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, USA</aff><aff id="aff3">
<label>c</label>Samsung Advanced Institute for Health Sciences &#x00026; Technology (SAIHST), Seoul, Korea</aff><pub-date pub-type="collection"><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub" iso-8601-date="2016-05-27"><day>27</day><month>5</month><year>2016</year></pub-date><volume>19</volume><issue>Suppl 1</issue><fpage seq="d">55</fpage><lpage>55</lpage><permissions><copyright-statement>&#x000a9; The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</copyright-statement><copyright-year>2016</copyright-year></permissions><self-uri xlink:href="pyw043.153.pdf"/><counts><page-count count="1"/></counts></article-meta></front><body><p>
<bold>Abstract</bold>
</p><p>Anxious depression, defined as major depressive disorder (MDD) accompanied by high levels of anxiety, seems to be difficult to treat with traditional antidepressant monotherapy. The purpose of this study was to assess the efficacy of ziprasidone monotherapy in patients with anxious depression versus non-anxious depression. One hundred and twenty outpatients were enrolled in a 12-week study that was divided into two 6-week periods according to the sequential parallel comparison design. Patients were randomized in a 2:3:3 multi-ratio to receive ziprasidone for 12 weeks, placebo for 6 weeks, followed by ziprasidone for 6 weeks, or placebo for 12 weeks. Efficacy was measured according to the 17-item Hamilton Depression Rating Scale (HRDS-17), Quick Inventory of Depressive Symptomatology Self-Rated (QIDS-SR). Anxious depression was defined as a score of &#x02265;7 on the HDRS-17 anxiety/somatization subscale. In phase I and II, ziprasidone monotherapy led to no significant changes compared with placebo on the HDRS-17 and QIDS-SR scores in patients with both anxious and non-anxious depression. In the pooled analysis, ziprasidone monotherapy also produced no significance on the HDRS-17 (Z = 0.25, P = 0.80) and QIDS-SR (Z = 0.43, P = 0.67) in patients with anxious depression. In conclusion, treatment with ziprasidone monotherapy may produce no significant improvement compared with placebo in patients with in anxious depression.</p><p>
<bold>Keywords:</bold> Ziprasidone; Major depressive disorder; Anxious depression; Efficacy; Monotherapy</p></body></article>